Currently, Summit is studying ivonescimab in the HARMONi, HARMONi-3, and HARMONi-7 trials. These trials are investigating the drug, respectively, as a second-line treatment for advanced EGFRm+ NSCLC; as a first-line treatment for metastatic NSCLC; and as a first-line treatment for metastatic PD-L1 high (≥50%) NSCLC. We should also note that, on October 17, Summit announced that it is starting the HARMONi-GI3 study, the first global Phase 3 trial of ivonescimab to look beyond NSCLC. The new study, planned to ...

公司评级与目标价 - RBC Capital维持对公司“行业持平”的评级 建议投资者持有头寸 [1] - RBC Capital将公司目标价从320美元下调至315美元 [2][5] 股价表现与交易数据 - 当前股价为281.89美元 当日小幅下跌0.68% [2] - 当日交易区间介于280.46美元的低点和285.08美元的高点之间 [3] - 过去52周股价波动较大 高点为302.24美元 低点为201.63美元 [3] - 自上次评估以来 公司总回报率表现强劲 跑赢标普500指数约10% [2][5] 公司基本面与市场地位 - 公司是运输行业主要参与者 专注于铁路货运服务 与联合太平洋和CSX公司等巨头竞争 [1] - 公司市值约为632.5亿美元 交易量为693,595股 显示出强劲的投资者兴趣 [4] 潜在催化剂与影响因素 - 与联合太平洋的潜在交易可能在明年对公司产生重大影响 [4][5] - 俄亥俄州脱轨事故等风险因素可能延迟公司价值完全实现 [3]

公司概况与市场地位 - 公司为一家主要运输企业 专注于美国东部的铁路货运服务 [1] - 公司在行业中与CSX Corporation和Union Pacific等铁路巨头竞争 [1] - 公司市值约为631.8亿美元 在行业中具有重要地位 [4] 近期股价表现与交易情况 - 当前股价为281.58美元 当日小幅下跌2.25美元 跌幅约0.79% [3] - 当日股价波动区间在281.02美元至285.08美元之间 [3] - 过去52周股价波动较大 最高达302.24美元 最低为201.63美元 [3] - 纽约证券交易所交易量为391,369股 显示投资者兴趣活跃 [4] 分析师观点与目标价 - RBC Capital分析师Walter Spracklin设定了315美元的目标价 [1] - 该目标价较当前281.50美元的股价有11.9%的潜在上涨空间 [1] 近期公司活动与市场关注 - 公司于2025年10月23日举行了2025年第三季度财报电话会议 [2] - 电话会议出席者包括总裁兼首席执行官Mark George及其他高管 [2] - 来自Wolfe Research和Barclays Bank等主要金融机构的分析师参与了会议 显示市场对公司财务表现和战略方向的高度关注 [2]

ATLANTA, April 23, 2025 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) announced Wednesday its first quarter 2025 financial results. For the quarter, revenue was $3.0 billion, income from railway operations was $1.1 billion, operating ratio was 61.7%, and diluted earnings per share were $3.31. After adjusting the results to exclude the Eastern Ohio incident, first quarter income from railway operations was $961 million, the operating ratio was 67.9%, and diluted earnings per share were $2.69. Insu ...